

Trovagene announces agreement with Novogene

July 13, 2017 | News

Through this agreement, Novogene will purchase NextCollect, Trovagene's proprietary urine collection and nucleic acid preservation device for validation in the Chinese market.



Trovagene, Inc. has entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequencing capacity in the world.

Through this agreement, Novogene will purchase NextCollect, Trovagene's proprietary urine collection and nucleic acid preservation device for validation in the Chinese market.

Trovagene will sell Novogene the NextCollect urine collection and stabilization device, in addition to reagents and methods to extract cell-free DNA (cfDNA) from urine. Novogene plans to validate the urine DNA extraction methods at their facilities, including their lab in Tianjin, China, which is accredited by the College of American Pathologists (CAP).

NextCollect is a first of its kind, proprietary urine collection and nucleic acid preservation device for research use only (RUO) by pharmaceutical companies, clinical research organizations and genomics laboratories. NextCollect is designed to preserve urinary DNA in applications such as oncology, infectious disease, urology, and transplantation.

NextCollect stabilizes up to 200 ml of a urine sample for 2 weeks at room temperature, and can be directly incorporated into laboratory processing without the need for an initial sample transfer. When coupled with Trovagene's proprietary nucleic acid isolation methods, NextCollect enables a significant advancement in the quality and quantity of DNA isolated from urine.